Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05116202 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

A Phase 1 study of Melanoma, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
110
Enrollment target
14
Study locations

NCT05116202 is a Phase 1 study of Melanoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 110 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (84% lower). The trial reports 14 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05116202, a Phase 1 study of Melanoma, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
110 participants
Enrollment target
14
Study locations

Study Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV melanoma (Cohort 2). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and modify the participant population.

Conditions Studied

Melanoma

Interventions

  • DRUG Atezolizumab
  • DRUG Nivolumab
  • DRUG Ipilimumab
  • DRUG Tiragolumab
  • DRUG RO7247669 2100 mg

Study Locations (14)

Other

  • Hopital de la Timone - Marseille
  • APHP - Hospital Saint Louis - Paris
  • Institut Universitaire du Cancer de Toulouse-Oncopole - Toulouse
  • Institut Gustave Roussy - Villejuif
  • Hospital Universitario Vall d Hebron - Barcelona

California

  • City of Hope - Duarte
  • The Angeles Clinic and Research Institute - W LA Office - Los Angeles

Florida

  • Moffitt Cancer Center - Tampa

Texas

  • MD Anderson Cancer Center - Houston

New South Wales

  • Melanoma Institute Australia - North Sydney

Abruzzo

  • Azienda Ospedaliera Universitaria Senese - Siena

Campania

  • Istituto Nazionale Tumori Fondazione G. Pascale - Naples

Lombardy

  • Istituto Europeo Di Oncologia - Milan

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2022-02-02
Est. Completion 2024-05-28
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05116202

The ClinicalTrials.gov registry entry for NCT05116202 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (84% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.

NCT05116202 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05116202 about?

NCT05116202 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)". This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV melanoma (Cohort 2). The study is designed with the flexibility to open new t...

What is the current status of trial NCT05116202?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2022-02-02. Estimated completion is 2024-05-28.

What conditions does trial NCT05116202 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT05116202?

The interventions under investigation include: Atezolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Tiragolumab (DRUG), RO7247669 2100 mg (DRUG).

Who is sponsoring clinical trial NCT05116202?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05116202 being conducted?

This trial has 14 study locations across California, Florida, Texas, New South Wales, Abruzzo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.